Review Article
The Role of Anticoagulation Clinics in the Era of New Oral Anticoagulants
Table 2
Principal characteristics of new oral anticoagulants ([
18,
19], modified).
| | Dabigatran | Rivaroxaban | Apixaban | Edoxaban |
| Target | IIa | Xa | Xa | Xa | Prodrug | Yes | No | No | No | Hours to | 2 | 2–4 | 1–3 | 1.5 | Bioavailability | 7% | 80% | 66% | 50% | Half-life (hours) | 12–14 | 9–13 | 8–15 | 6–11 | CYP metabolism | No | Yes | Yes | Yes | Efflux transporter P-gp | Yes | Yes | Yes | Yes | Renal elimination | 80% | 66% (33% cleared unchanged) | 25% | 35% | Dosing | Bid | Od | Bid | Od |
|
|